Skip to content
Head to head

Nanobiotix vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: NBTX · VRTX

Updated 3 minutes ago

1-year performance, rebased to 100

NBTX +21.1%VRTX +18.7%
It’s close.
NBTXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price26.50515.02
Change today-2.98%-1.08%
1-year return+30.0%+22.0%
Market cap$1.35B$130.58B
52-week range19.14 – 57.14412.27 – 568.67
Valuation
P/E (TTM)-22.1833.14
P/E percentile, own 5-yr range11th99th
P/B-36.866.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.5515.32
Net profit (TTM)$-27.92M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date--2026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin-353.6%33.1%
Net margin-632.5%30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date--2026-09-29
Ownership & sentiment
Institutional ownership43.7%96.8%
Insider activity (12mo)0 buy / 0 sell28 buy / 22 sell
Short interest (% of float)0.3%1.9%
Analyst consensus100% buy (2)95% buy / 5% hold (21)
Analyst price target$64 (+142%)$624 (+21%)
StockVane view
StockVane Quant RatingD (68)C (62)
Company
Employees976,400
Founded20031989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.